Neurophysiological and Neurocognitive Endophenotypes for Schizophrenia Genetics Research

Yeon Ho Joo, MD, PhD
Department of Psychiatry,
University of Ulsan
College of Medicine,
Asan Medical Center,
Seoul, Korea

Concept for Endophenotype

Genetics is all about the relationship between the underlying genotype and manifested phenotypes. The hunt for disease-related genes has proven to be more difficult than was initially anticipated and has been successful mostly in disorders that are clearly defined and homogenous. Psychotic disorders have posed a particularly difficult problem, due to the lack of preciseness in defining the boundaries of the clinical phenotype and the absence of objective, biological tests that confirm the diagnostic categorization. In complex diseases such as schizophrenia, there might be a long and winding pathway between the candidate genes and the clinical diagnosis. In schizophrenia, a large amount of genetic studies have been done to elucidate the susceptibility genes that underlie the phenotype. Until now, there have been no widely accepted susceptibility genes that are related to schizophrenia, even though there is well established evidence that schizophrenia has substantial genetic components.

This is where the concept of the endophenotype comes in. This concept was first introduced into the schizophrenia literature by Gottesman and Shields in 1972 and was designed to signify quantitative measures that were “intermediate”, functionally important links in the pathways between genetic variation and the clinical expression of the disorder.1 Other terms have been used interchangeably, such as the intermediate phenotype, biological marker, subclinical trait, and vulnerability marker. These terms may not necessarily reflect genetic underpinnings, but rather associated findings.

Other fields of medicine have had some success in using endophenotypes for genetic studies. For example, the multiple genes causing long QT syndrome were identified by using QT elongation, as measured by electrocardiogram (ECG), rather than by using the phenotypes of syncope, ventricle arrhythmias, and sudden death.2,3

One strategy to dissect the complex nature of schizophrenia is the analysis of the quantitative neurobiological deficits, endophenotypes, that are present in schizophrenia patients and their first-degree biological relatives.4 As relatively simple, quantifiable biobehavioral characteristics, individual endophenotypes are presumably determined by
fewer genes than the more complex phenotype of schizophrenia. Endophenotypes were originally defined as measurable components unseen by the unaided eye along the pathway between the disease and distal genotype.4

An endophenotype-based approach has the potential advantage of facilitating the genetic dissection of schizophrenia, because they would ideally have monogenic roots. In reality, however, an endophenotype is a rather ill-defined construct that probably involves neurophysiological, biochemical, endocrinological, neuroanatomical, cognitive and even neuropsychological factors.5 Hence, the use of endophenotypes needs to be tempered by the appreciation that without controls and limits, their usefulness may be obscured. A putative endophenotype does not necessarily reflect genetic effects. Indeed, these biological markers may be environmental, epigenetic, or multifactorial in origin. However, it psychiatric diagnoses could be decomposed or deconstructed, I could render the genetic analysis more straightforward.

Criteria for Endophenotypes

A number of criteria for evaluating the validity of candidate endophenotypes have been suggested.5,6,9 Among them, the following criteria have been the most frequently adopted.

1. The endophenotype should be heritable.
2. The endophenotype should be state-independent.
3. The endophenotype should be associated with illness in the population.
4. Within families, endophenotype and illness should co-segregate.

The final criterion for an endophenotypic marker has two distinct components. First, the marker must co-segregate with the illness within a family. The second component specifically relates to diseases with complex inheritance patterns. In this case, unaffected family members should show some level of disruption on the marker compared with the population at large.10

In psychiatric fields, a number of attempts have been made to develop and determine the feasibility of candidate endophenotypes. However, few have met all the criteria listed until now.4

Neurophysiological Endophenotypes

The ideal neuropsychiological endophenotype is one that exhibits a robust and stable deficit in both patients and unaffected family members and shows strong evidence of both heritability and co-segregation with illness within pedigrees. It should also be easily and rapidly measured with minimal demands on the subject, demonstrate excellent test-retest and across-site reliability and, preferably, reflect a discrete neurobiological mechanism that is both informative for the pathophysiology of the disorder and regulated by a limited number of genes.11

Inhibitory deficits in schizophrenia have been recognized since long ago.12 Patients with schizophrenia are unable to screen out trivial stimuli and focus on salient aspects of the environment. Patients with schizophrenia exhibit deficits in several neurophysiological measures of information processing that have been proposed as candidate endophenotypes. Measures of inhibitory failure include prepulse inhibition of the startle reflex, P50 auditory evoked potential suppression, and antisaccade eye movements. For example, the neurophysiological measures in Consortium on the Genetics of Schizophrenia (COGS) include P50 auditory evoked potential suppression, prepulse inhibition (PPI) of the startle reflex, and antisaccade (AS) eye movements. Measures of impaired deviance detection include mismatch negativity and the P300 event-related potential.

The P50 suppression test uses two auditory stimuli presented at 500-msec intervals. The P50 wave is a midlatency auditory evoked potential that exhibits reduced amplitude, or suppression, when a second click sound is presented 500 ms after the initial click. Freedman et al. identified p50 suppression as an important endophenotype of schizophrenia.13 The use of p50 suppression as a candidate endophenotype for genetic studies is further supported by the identification of significant linkage of p50 suppression with a genetic marker in the promoter region of the alpha-7 subunit of the nicotinic receptor.14

PPI is the normal reduction in startle that occurs when a starting stimulus is preceded 30–300 ms by a weak prestimulus.15 Prepulse inhibition is a generally conserved finding among vertebrates and, as such, it has been the target of several rodent studies.9 It is also deficient in patients with schizophrenia and their relatives.16,17 Abnormal prepulse inhibitions were found in obsessive compulsive disorder18 and Huntington’s disease,19 among others. Elements of the cortico-striato-pallido-thalamic circuitry in humans and animal models are known to be implicated in the neural regulation of PPI.20

The saccadic performance in schizophrenia patients is characterized by an increased proportion of antisaccade errors.21 In their more proximal connection to neuronal mechanisms, neurophysiological endophenotypes are a much stronger signal for the putative disease-related genes, compared to more variable and complex clinical phenotypes.22

Neurophysiological measures used in the genetic study of schizophrenia are summarized in Table 1.
TABLE 1. Neurophysiological measures used in the genetic study of schizophrenia

| Neurophysiological measure | Neurocognitive construct |
|----------------------------|--------------------------|
| PPI (Prepulse inhibition) of startle reflex | Sustained attention |
| P50 auditory evoked potential suppression | DS-CPT / CPT-IP |
| AS (antisaccade) eye movements | Verbal declarative memory |
| Mismatch negativity | Working memory |
| P300 event-related potential | LNS |

TABLE 2. Neurocognitive construct and measures used in the genetic study of schizophrenia

| Neurocognitive construct | Neurocognitive measures |
|--------------------------|-------------------------|
| Sustained attention | DS-CPT / CPT-IP |
| Verbal declarative memory | WMS-III, LM / CVLT-II |
| Working memory | LNS |

Neurocognitive construct and measures most frequently used in the genetic study of schizophrenia are summarized in Table 2.

Conclusion

The endophenotype strategy could be a powerful and effective means of identifying vulnerability genes in schizophrenia. There is, however, little convincing evidence yet that the genetic architecture of the endophenotypes is substantially simpler than that of the schizophrenia itself. Many of the endophenotypes remain complex, thereby decreasing their utility in a genetic study. Further studies need to be done before endophenotypic measures can be used in the genetic analysis of schizophrenia.

REFERENCES

1. Gottesman II, Shields J. Schizophrenia and genetics: a twin study vantage point. New York: Academic Press; 1972.
2. Keating M, Atkinson D, Dunn C, Timothy K, Vincent GM, Leppert M. Linkage of a cardiac arrhythmia, the long QT syndrome, and the Harvey ras-1 gene. Science 1991;252:704-706.
3. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992;327:846-852.
4. Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003;160:636-645.
5. Benes FM. Searching for unique endophenotypes for schizophrenia and bipolar disorder within neural circuits and their molecular regulatory mechanisms. Schizophr Bull 2007;33:932-936.
6. Almasy L, Blangero J. Endophenotypes as quantitative risk factors for psychiatric disease: rationale and study design. Am J Med Genet 2001;105:42-44.
7. Conblatt BA, Malhotra AK. Impaired attention as an endophenotype for molecular genetic studies of schizophrenia. Am J Med Genet 2001;105:11-15.
8. Doyle AE, Willcutt EG, Seidman LJ, Biederman J, Chouinard VA, Silva J, et al. Attention-deficit/hyperactivity disorder endophenotypes. Biol Psychiatry 2005;57:1324-1335.
9. Waldman ID. Statistical approaches to complex phenotypes: evaluating neuropsychological endophenotypes for attention-deficit/hyperactivity disorder. Biol Psychiatry 2005;57:1347-1356.
10. Glahn DC, Bearden CE, Niendam TA, Escamilla MA. The feasibility of neuropsychological endophenotypes in the search for genes associated with bipolar affective disorder. Bipolar Disord 2004;6:171-182.
11. Turetsky BI, Calkins ME, Light GA, Olincy A, Radant AD, Swerdlow YH Joo
Endophenotypes for Schizophrenia

NR. Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures. Schizophr Bull 2007;33:69-94.
12. McGhie A, Chapman J. Disorders of attention and perception in early schizophrenia. Br J Med Psychol 1961;34:103-116.
13. Freedman R, Adler LE, Waldo MC, Pachtman E, Franks RD. Neurophysiological evidence for a defect in inhibitory pathways in schizophrenia: comparison of medicated and drug-free patients. Biol Psychiatry 1983;18:537-551.
14. Freedman R, Coon H, Myles-Worsley M, Orr-Utregre A, Olincy A, Davis A. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci U S A 1997;94:587-592.
15. Graham FK. Presidential Address, 1974. The more or less startling effects of weak prestimulation. Psychophysiology 1975;12:238-248.
16. Braff D, Stone C, Callaway E, Geyer M, Glick I, Bali L. Prestimulus effects on human startle reflex in normals and schizophrenics. Psychophysiology 1978;15:339-343.
17. Cadenhead KS, Swerdlow NR, Shafer KM, Diaz M, Braff DL. Modulation of the startle response and startle laterality in relatives of schizophrenic patients and in subjects with schizotypal personality disorder: evidence of inhibitory deficits. Am J Psychiatry 2000;157:1660-1668.
18. Swerdlow NR, Benbow CH, Zisook S, Geyer MA, Braff DL. A preliminary assessment of sensorimotor gating in patients with obsessive compulsive disorder. Biol Psychiatry 1993;33:298-301.
19. Swerdlow NR, Paulsen J, Braff DL, Butters N, Geyer MA, Swenson MR. Impaired prepulse inhibition of acoustic and tactile startle response in patients with Huntington’s disease. J Neurol Neurosurg Psychiatry 1995;58:192-200.
20. Swerdlow NR, Geyer MA, Braff DL. Neural circuit regulation of prepulse inhibition of startle in the rat: current knowledge and future challenges. Psychopharmacology (Berl) 2001;156:194-215.
21. Fukushima J, Morita N, Fukushima K, Chiba T, Tanaka S, Yamashita I. Voluntary control of saccadic eye movements in patients with schizophrenic and affective disorders. J Psychiatr Res 1990;24:9-24.
22. Braff DL, Greenwood TA, Swerdlow NR, Light GA, Schork NJ. The Investigators of the Consortium on the Genetics of Schizophrenia. Advances in endophenotyping schizophrenia. World Psychiatry 2008;7:11-18.
23. Calkins ME, Dobie DJ, Cadenhead KS, Olincy A, Freedman R, Green MF, et al. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull 2007;33:33-48.
24. Wechsler D. Wechsler Memory Scale, third edition. San Antonio, Texas: The Psychological Corporation, Harcourt Brace & Company; 1997.
25. Delis D, Kramer J, Kaplan E, Ober B. California Verbal Learning Test, second edition. Adult Version. Manual. New York, New York: The Psychological Corporation: 2000.
26. Goldman-Rakic PS. Working memory dysfunction in schizophrenia. In: Salloway SP, Malloy PF, Duffy ID, editors. The Frontal Lobe and Neuropsychiatric Illness. Washington, DC: American Psychiatric Publishing, Inc., 2001, p.71-82.
27. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”? Schizophr Bull 2000;26:119-136.
28. Kopelowicz A, Liberman RP, Ventura J, Zanate R, Mintz J. Neurocognitive correlates of recovery from schizophrenia. Psychol Med 2005; 35:1165-1173.
29. Gur RE, Calkins ME, Gur RC, Horan WP, Nuechterlein KH, Seidman LJ, et al. The Consortium on the Genetics of Schizophrenia: neurocognitive endophenotypes. Schizophr Bull 2007;33:49-68.
30. Keefe RS, Seidman LJ, Christensen BK, Hamer RM, Sharma T, Sitskoorn MM, et al. Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. Am J Psychiatry 2004;161:985-995.